Allergan
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Allergan sits in the top decile of US sponsors by registered trial count (#114 of 15,742 sponsors by registered trial count).
Allergan: 314 sponsored US clinical trials, none currently recruiting.
Allergan sponsors 314 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 278 completed. 142 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ocular Hypertension, with 9 trials.
Top-decile sponsor footprint
Allergan ranks in the top decile of sponsors by registered trial count (#114 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
278 of 313 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
314 total, page 3 of 7
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
NCT02188173
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
NCT02176356
Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea
NCT02132117
OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)
NCT02097121
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT02087085
Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
NCT02097719
Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
NCT02131636
A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects
NCT02155543
OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
NCT02145676
Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease
NCT02013791
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
NCT02116361
Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy
NCT02121847
A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea
NCT02095158
A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
NCT02147197
A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache
NCT01946126
A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas
NCT02147158
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
NCT01852058
A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris
NCT02032407
A Safety and Effectiveness Study of JUVÉDERM VOLBELLA® XC Injectable Gel for Lip and Perioral Enhancement
NCT01998581
Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction
NCT01979887
A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds
NCT01976663
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
NCT01945489
JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines
NCT01970397
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
NCT01930786
A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation
NCT01917006
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
NCT01918371
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
NCT01904721
Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
NCT01930799
Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients
NCT01852045
A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions
NCT01879683
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
NCT01830140
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
NCT01863953
A Study to Compare a New Eye Drop Formulation With Refresh Contacts®
NCT01844388
NATRELLE® 410 X-Style and L-Style Breast Implants Continued Access Study
NCT01870869
A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
NCT01749410
Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
NCT01833130
Bimatoprost for the Treatment of Eyebrow Hypotrichosis
NCT01765764
A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
NCT01767519
Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classification
NCT01821534
Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
NCT01824303
Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris
NCT01773122
A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia
NCT01678924
Safety and Effectiveness of NATRELLE® 410 Highly Cohesive, Anatomically Shaped, Silicone-filled X-Style and L-Style Breast Implants
NCT01785069
AGN-199201 for the Treatment of Erythema With Rosacea
NCT01735201
BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity
NCT01603641
Bimatoprost in the Treatment of Eyelash Hypotrichosis
NCT01698554
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
NCT01732757
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
NCT01603615
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
NCT01662492
BOTOX® Treatment in Pediatric Lower Limb Spasticity
NCT01603628
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 85 |
| Phase 3 | 91 |
| Phase 4 | 51 |
Therapeutic Areas
How the Allergan archive is shaped
314 indexed studies, none listed as recruiting (0% open); 278 completed (89%).
Phase mix: 142 late (III/IV) vs 114 early (I/II) (balanced across stages).
Top condition: Ocular Hypertension (9 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Allergan: archived-pipeline peers nationwide
Peers matched on 314 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Allergan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 314 archived trials
- University of Arkansas · 318 trials · 12% recruiting
- Rush University Medical Center · 320 trials · 17% recruiting
- Celgene · 308 trials · 4% recruiting
- Jonsson Comprehensive Cancer Center · 321 trials · 19% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Allergan page
314 registered trials is a research-attention snapshot, not an endorsement of Allergan or any single study.
- None of Allergan's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Ocular Hypertension is the condition Allergan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ocular Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Allergan pipeline card: 314 registered trials from official public datasets.Report a data error.